LGNZZ Stock Price, Chart, Stats & News

Ligand Pharmaceuticals, Inc. operates as a global biopharmaceutical firm dedicated to advancing and licensing pharmaceutical assets. The company's portfolio features a diverse array of therapies addressing critical health conditions. Key products include Kyprolis and Evomela, both indicated for multiple myeloma; Rylaze, an effective treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in pediatric and adult populations; and Filspari, a dual antagonist in development for rare kidney diseases and immunoglobulin A nephropathy.